10:21 AM EST - BioVaxys Technology Corp : Announces positive preliminary results from the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab and cyclophosphamide in patients with recurrent epithelial ovarian cancer. BioVaxys Technology Corp
shares C.BIOV are trading off $0.01 at $0.25.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=4601800385716755
